Last Updated : May 11, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area Sort ascending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Imfinzi | Durvalumab | Unresectable Non-Small Cell Lung Cancer (NSCLC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Stivarga | Regorafenib | Unresectable Hepatocellular Carcinoma (HCC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Imfinzi and Imjudo | durvalumab and tremelimumab | unresectable hepatocellular carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Xeljanz | tofacitinib | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete | ||
Stelara/Stelara I.V | ustekinumab | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete | ||
Entyvio | vedolizumab | Ulcerative Colitis | Reimburse with clinical criteria and/or conditions | Complete | ||
Entyvio | Vedolizumab | Ulcerative colitis | List with clinical criteria and/or conditions | Complete | ||
Humira | Adalimumab | Ulcerative colitis | Do not list at the submitted price | Complete | ||
Simponi | Golimumab | Ulcerative colitis | Do not list at the submitted price | Complete | ||
Humira | Adalimumab | ulcerative colitis | Withdrawn |